Back to Search Start Over

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial

Authors :
Seong bong Han
Han Chu Lee
Young-Suk Lim
Yung Sang Lee
Ju Hyun Shim
Jihyun An
Wonhee Jeong
Gi Ae Kim
Danbi Lee
Source :
BMC Gastroenterology
Publisher :
Springer Nature

Abstract

Background Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment. Methods In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and 0.5 log10 IU/mL. Eleven patients (23.4%) in the telbivudine group, but none in the entecavir group, experienced virologic breakthrough (P

Details

Language :
English
ISSN :
1471230X
Volume :
17
Issue :
1
Database :
OpenAIRE
Journal :
BMC Gastroenterology
Accession number :
edsair.doi.dedup.....e315edc10176dec53989156da3c94830
Full Text :
https://doi.org/10.1186/s12876-017-0572-2